Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies

Trial Profile

An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palupiprant (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Eisai Inc

Most Recent Events

  • 27 Sep 2022 Results (n=48) of Population pharmacokinetic analysis( from two phase 1 studies NCT02540291 and NCT03152370) to characterize the pharmacokinetic profle of orally administered AN0025 after single and multipledoses in cancer patients presented at the 2022 American College of Clinical Pharmacology Annual Meeting
  • 30 Jul 2018 Status changed from recruiting to discontinued.
  • 12 Sep 2017 Results (n=30) presented at the 42nd European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top